Literature DB >> 8325300

Increased cardiac sympathetic nervous activity in patients with unstable coronary heart disease.

A J McCance1, P A Thompson, J C Forfar.   

Abstract

We have evaluated overall and cardiac sympathetic activity in 47 patients undergoing coronary angiography, 27 with stable angina of at least 3 months duration, and 20 with unstable ischaemic symptoms within this period. Cardiac and overall sympathetic activity were assessed using radiotracer noradrenaline kinetic techniques to measure cardiac and total noradrenaline spillover to plasma. Overall sympathetic activity (whole body noradrenaline spillover) was similar in the two groups, whereas cardiac sympathetic activity (cardiac noradrenaline spillover) was strikingly increased in the patients with unstable ischaemic symptoms (102 +/- 23 pmol.min-1 vs 34 +/- 4 pmol.min-1, P < 0.001), as was the cardiac to whole body noradrenaline spillover ratio (0.043 +/- 0.008 vs 0.021 +/- 0.005, P < 0.01). Coronary sinus bloodflow (50 +/- 4 ml.min-1 vs 38 +/- 4 ml.min-1, P < 0.05) and coronary sinus noradrenaline concentration (2.60 +/- 0.38 nmol.l-1 vs 1.41 +/- 0.17 nmol.l-1, P < 0.01) were also increased in the patients with unstable ischemic syndromes. Left ventricular ejection fraction was similar in the two groups (63 +/- 2% vs 62 +/- 2%). Patients with unstable ischaemic symptoms within the previous three months have increased cardiac sympathetic nervous activity compared to patients with stable angina. This may in part explain why patients with unstable ischaemic syndromes are at increased risk of sudden cardiac death.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8325300     DOI: 10.1093/eurheartj/14.6.751

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  9 in total

Review 1.  Advances in the early diagnosis and management of acute myocardial infarction.

Authors:  R Vincent
Journal:  J Accid Emerg Med       Date:  1996-03

Review 2.  Neuroendocrine activation after myocardial infarction: causes and consequences.

Authors:  J G Cleland; P J Cowburn; K Morgan
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 3.  Neuroendocrine activation after myocardial infarction.

Authors:  J Remes
Journal:  Br Heart J       Date:  1994-09

Review 4.  Effects of ACE inhibitors on coronary haemodynamics and angina pectoris.

Authors:  M K Davies
Journal:  Br Heart J       Date:  1994-09

Review 5.  Sympathetic nerve function--assessment by radioisotope dilution analysis.

Authors:  Graeme Eisenhofer
Journal:  Clin Auton Res       Date:  2005-08       Impact factor: 4.435

6.  Ranolazine Therapy Reduces Non-ST-Segment-Elevation Myocardial Infarction and Unstable Angina in Coronary Disease Patients with Angina.

Authors:  Gary L Murray; Joseph Colombo
Journal:  Int J Angiol       Date:  2016-04-28

7.  Spinal cord stimulation in pain management: a review.

Authors:  Young Hoon Jeon
Journal:  Korean J Pain       Date:  2012-06-28

8.  Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial.

Authors:  Anna Meta Dyrvig Kristensen; Ann Bovin; Ann Dorthe Zwisler; Charlotte Cerquira; Christian Torp-Pedersen; Hans Erik Bøtker; Ida Gustafsson; Karsten Tange Veien; Kristian Korsgaard Thomsen; Michael Hecht Olsen; Mogens Lytken Larsen; Olav Wendelboe Nielsen; Per Hildebrandt; Sussie Foghmar; Svend Eggert Jensen; Theis Lange; Thomas Sehested; Tomas Jernberg; Dan Atar; Borja Ibanez; Eva Prescott
Journal:  Trials       Date:  2020-05-23       Impact factor: 2.279

9.  Preserved Autonomic Cardiovascular Regulation With Cardiac Pacemaker Inhibition: A Crossover Trial Using High-Fidelity Cardiovascular Phenotyping.

Authors:  Karsten Heusser; Jens Tank; Julia Brinkmann; Christoph Schroeder; Marcus May; Anika Großhennig; Daniela Wenzel; André Diedrich; Fred C G J Sweep; Heidrun Mehling; Friedrich C Luft; Jens Jordan
Journal:  J Am Heart Assoc       Date:  2016-01-13       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.